BRAF and cancer: We found BRAF mutation to be significantly associated with high RI values (Wilcox p-value THCA < 2e−16, SKCM 2e−3) (Fig. 6e) suggesting BRAF to be a key driver of oncogenic RAS pathway activity in these two cancers.